KUMAMOTO University

R

研究業績RESEARCH ACHIEVEMENTS

  1. Nosaka K and Matsuoka M

    Adult T-cell leukemia-lymphoma as a viral disease: subtypes based on viral aspects.

    ancer Sci 112(5):1688-1694. doi: 10.1111/cas.14869. Epub 2021 Mar 30.

    https://pubmed.ncbi.nlm.nih.gov/33630351/

     

     

  2. Guangyong Ma, Jun-ichirou Yasunaga, Kazuya Shimurab, Keiko Takemotob, Miho Watanabec, Masayuki Amano, Hirotomo Nakata, Benquan Liua, Xiaorui Zuoa, and Masao Matsuoka

    Human retroviral antisense mRNAs are retained in the nuclei of infected cells for viral persistence

    Proc Natl Acad Sci U S A.2021 Apr 27;118(17):e2014783118. doi: 10.1073/pnas.2014783118.

    https://pubmed.ncbi.nlm.nih.gov/33875584/

     

     

  3. Huang J, Gou H, Yao J, Yi K, Jin Z, Matsuoka M and Zhao T

    The noncanonical role of EZH2 in cancer.

    Cancer Sci 112(4):1376-1382. doi: 10.1111/cas.14840. Epub 2021 Feb 24.

    https://pubmed.ncbi.nlm.nih.gov/33615636/

     

  4. Penova M, Kawaguchi S, Yasunaga JI, Kawaguchi T, Sato T, Takahashi M, Shimizu M, Saito M, Tsukasaki K, Nakagawa M, Takenouchi N, Hara H, Matsuura E, Nozuma S, Takashima H, Izumo S, Watanabe T, Uchimaru K, Iwanaga M, Utsunomiya A, Tabara Y, Paul R, Yamano Y, Matsuoka M and Matsuda F.

    HTLV-1 associated myelopathy/tropical spastic paraparesis in the Japanese population – a genome-wide association study.

     Proc Natl Acad Sci USA 118(11):e2004199118. doi: 10.1073/pnas.2004199118.

    https://pubmed.ncbi.nlm.nih.gov/33649182/

     

  5. Izaki M, Yasunaga JI, Nosaka K, Sugata K, Utsunomiya H, Suehiro Y, Shichijo T, Yamada A, Sugawara Y, Hibi T, Inomata Y, Akari H, Melamed A, Bangham C, Matsuoka M.

    In vivo dynamics and adaptation of HTV-1-infected clones under different clinical conditions

    PLOS Pathogens.2021 Feb 1;17(2):e1009271. doi: 10.1371/journal.ppat.1009271. Online ahead of print .PMID: 33524072

    https://pubmed.ncbi.nlm.nih.gov/33524072/

     

  6. Nozaki K, Maruyama D, Maeshima AM, Tajima K, Itami J, Shichijo T, Yuda S, Suzuki T, Toyoda K, Yamauchi N, Makita S, Fukuhara S, Munakata W, Kobayashi Y, Taniguchi H, Izutsu K and Tobinai K.

    The role of local radiotherapy following rituximab-containing chemotherapy in patients with transformed indolent B-cell lymphoma.

    Eur J Haematol 106(2): 213-220. doi: 10.1111/ejh.13539. Epub 2020 Nov 6.

    https://pubmed.ncbi.nlm.nih.gov/33098704/

     

     

  7. Shichijo T, Maruyama D, Yamauchi N, Maeshima AM, Sugano M, Yuda S, Tajima K, Kurihara H, Shimada K, Suzuki T, Toyoda K, Makita S, Fukuhara S, Munakata W, Suzuki T, Kobayashi Y, Taniguchi H, Minami Y, Izutsu K and Tobinai K.

    Transformation Scoring System (TSS): A new assessment index for clinical transformation of follicular lymphoma.

    Cancer Med 9(23): 8864-8874. doi: 10.1002/cam4.3501. Epub 2020 Oct 6.

    https://pubmed.ncbi.nlm.nih.gov/33022120/

     

  8. Tanaka A, Ishitsuka Y, Ohta H, Fujimoto A, Yasunaga JI, Matsuoka M.

    Systematic clustering algorithm for chromatin accessibility data and its application to hematopoietic cells.

    PLOS Comput Biol 16(11):e1008422. doi: 10.1371/journal.pcbi.1008422. eCollection 2020 Nov.

    https://pubmed.ncbi.nlm.nih.gov/33253153/

     

  9. Hashiguchi Y, Oda K, Katanoda T, Nosaka K, Jono H and Saito H

    Clinical evaluation of cefotiam in the treatment of bacteremia caused by Escherichia coli, Klebsiella species, and Proteus mirabilis: A retrospective study.

    J Infect Chemother 26(11):1158-1163. doi: 10.1016/j.jiac.2020.06.007. Epub 2020 Aug 20.

    https://pubmed.ncbi.nlm.nih.gov/32828676/

     

  10. Kimura Y, Iwanaga E, Iwanaga K, Endo S, Inoue Y, Tokunaga K, Nagahata Y, Masuda K, Kawamoto H, Matsuoka M.

    A regulatory element in the 3′-untranslated region of CEBPA is associated with myeloid/NK/T-cell leukemia.

    Eur J Haematol. 2020 Nov 16.doi:10.1111/ejh.13551. PMID:33197296

    https://pubmed.ncbi.nlm.nih.gov/33197296/

     

  11. Imaizumi Y, Iwanaga M, Nosaka K, Ishitsuka K, Ishizawa K, Ito S, Amano M, Ishida T, Uike N, Utsunomiya A, Ohshima K, Tanaka J, Tokura Y, Tobinai K, Watanabe T, Uchimaru K and Tsukasaki K for collaborative Investigators.

    Prognosis of patients with adult T-cell leukemia/lymphoma in Japan: A nationwide hospital-based study.

    Cancer Sci 111(12): 4567-4580. doi: 10.1111/cas.14658. Epub 2020 Oct 21.

    https://pubmed.ncbi.nlm.nih.gov/32976684/

     

  12. Nakamura T, Nakamura T, Amano M, Miyakawa T, Yamagata Y, Matsuoka M, Nakata H.
    A Conformational Escape Reaction of HIV-1 against an Allosteric Integrase Inhibitor.
    J Virol. 2020 Sep 15;94(19):e00486-20. doi: 10.1128/JVI.00486-20. PMID: 32611758; PMCID: PMC7495394

  13. Higuchi Y, Yasunaga JI, Mitagami Y, Tsukamoto H, Nakashima K, Ohshima K, Matsuoka M.

    HTLV-1 induces T cell malignancy and inflammation by viral antisense factor-mediated modulation of the cytokine signaling.

    Proc Natl Acad Sci U S A. 2020 Jun 16;117(24):13740-13749. doi: 10.1073/pnas.1922884117. Epub 2020 May 29.

    https://pubmed.ncbi.nlm.nih.gov/32471947/

     

     

  14. Ghosh AK, Kovela S, Osswald HL, Amano M, Aoki M, Agniswamy J, Wang YF, Weber IT, Mitsuya H.
    Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies.
    J Med Chem. 2020 May 14;63(9):4867-4879. doi: 10.1021/acs.jmedchem.0c00202. PMID: 32348139; PMCID: PMC7425579

  15. Maeda M, Tanabe-Shibuya J, Miyazato P, Masutani H, Yasunaga JI, Usami K, Shimizu A, Matsuoka M.

    IL-2/IL-2 Receptor Pathway Plays a Crucial Role in the Growth and Malignant Transformation of HTLV-1-Infected T Cells to Develop Adult T-Cell Leukemia.

    Front Microbiol. 2020 Mar 6;11:356. doi: 10.3389/fmicb.2020.00356. eCollection 2020.

    https://pubmed.ncbi.nlm.nih.gov/32210945/

     

  16. Cui G, Shimba A, Ma G, Takahara K, Tani-Ichi S, Zhu Y, Asahi T, Abe A, Miyachi H, Kitano S, Hara T, Yasunaga JI, Suwanai H, Yamada H, Matsuoka M, Ueki K, Yoshikai Y, Ikuta K.

    IL-7R-Dependent Phosphatidylinositol 3-Kinase Competes with the STAT5 Signal to Modulate T Cell Development and Homeostasis.

    J Immunol. 2020 Feb 15;204(4):844-857. doi: 10.4049/jimmunol.1900456. Epub 2020 Jan 10.

    https://pubmed.ncbi.nlm.nih.gov/31924648/

     

  17. Nagafuji K, Matsumura I, Shimose T, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Kadowaki N, Ishikawa J, Imamura Y, Yamazaki H, Akashi K, Kanakura Y.

    Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt).

    Int J Hematol .2019 Dec;110(6):675-682. doi: 10.1007/s12185-019-02736-5. PMID: 31538327

  18. Shirayama R, Takedani H, Chikasawa Y, Ishiguro A, Ishimura M, Isobe K, Uchiba M, Ogata Y, Kakuda H, Kusuhara K, Shirahata A.

    Perioperative safety and haematostatic efficacy of a new bypassing agent pd-FVIIa/FX (Byclot) in haemophilia patients with high-responding type inhibitors.

    Blood Coagul Fibrinolysis.2019 Dec;30(8):385-392. doi: 10.1097/MBC.0000000000000851. PMID: 31738288

  19. Ishikawa M, Iriyama N, Tokuhira M, Takaku T, Sato E, Sugimoto K J, Nakazato T, Fujita H, Kimura Y, Fujioka I, Komatsu N, Asou N, Kizaki M, Hatta Y, Kawaguchi T.

    Potential role for secondgeneration tyrosine kinase inhibitors in patients with chronic myeloid leukemia harboring additional clonal chromosome abnormalities: A retrospective CML Cooperative Study Group analysis.

    Oncol Rep.2019 Dec;42(6):2836-2843. doi: 10.3892/or.2019.7339. Epub 2019 Sep 27. PMID: 31578586

  20. Takenaka K, Minami T, Yoshihashi Y, Hirata S, Kimura Y, Kono H.

    Decrease in MPO-ANCA after administration of benralizumab in eosinophilic granulomatosis with polyangiitis.

    Allergol Int.2019 Oct;68(4):539-540. doi: 10.1016/j.alit.2019.04.006. Epub 2019 May 9. PMID: 31080020

  21. Nishimura N, Radwan MO, Amano M, Endo S, Fujii E, Hayashi H, Ueno S, Ueno N, Tatetsu H, Hata H, Okamoto Y, Otsuka M, Mitsuya H, Matsuoka M, Okuno Y.

    Novel p97/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib-sensitive and -resistant multiple myeloma cells.

    Cancer Sci. 2019 Oct;110(10):3275-3287. doi: 10.1111/cas.14154. Epub 2019 Aug 14. PMID: 31368616; PMCID: PMC6778635.

    https://pubmed.ncbi.nlm.nih.gov/31368616/

     

  22. Onitsuka K, Tokuda R, Kuwata-Higashi N, Kumamoto H, Aoki M, Amano M, Kohgo S, Das D, Haraguchi K, Mitsuya H, Imoto S.

    Synthesis and evaluation of the anti-hepatitis B virus activity of 4′-Azido-thymidine analogs and 4′-Azido-2′-deoxy-5-methylcytidine analogs: structural insights for the development of a novel anti-HBV agent.

    Nucleosides Nucleotides Nucleic Acids. 2019 Sep 12;1-12. doi: 10.1080/15257770.2019.1664749. [Epub ahead of print]. PMID: 31514570.

    https://pubmed.ncbi.nlm.nih.gov/31514570/

  23. Noyori O, Komohara Y, Nasser H, Hiyoshi M, Ma C, Pan C, Carreras J, Nakamura N, Sato A, Ando K, Okuno Y, Nosaka K, Matsuoka M, and Suzu S.

    Expression of IL-34 correlates with macrophage infiltration and prognosis of diffuse large B-cell lymphoma.

    Clin Transl Immunology.2019 Aug 13;8(8):e1074. doi: 10.1002/cti2.1074. eCollection 2019. PMID: 31417675

    https://pubmed.ncbi.nlm.nih.gov/31417675/

     

  24. Iriyama N, Tokuhira M, Sato E, Sugimoto K J, Takaku T, Ishikawa M, Nakazato T, Fujita H, Kimura Y, Fujioka I, Asou N, Komatsu N, Kizaki M, Hatta Y, Kawaguchi T.

    Smoking influences the outcomes of patients receiving tyrosine kinase inhibitors for chronic myeloid leukemia in the chronic phase: A retrospective analysis.

    Hematol Oncol . 2019 Aug;37(3):323-325.doi: 10.1002/hon.2617. Epub 2019 Apr 26. PMID: 30950076

CONTACT US

C

  • 患者様へ

    外来診療の方は外来予約センターより
    ご予約をお願いいたします。
    外来予約センター

  • 学生・研修医・医療関係者の方へ

    TEL
    096-373-5156
    FAX
    096-373-5158
    Mail
    nikyo@kumamoto-u.ac.jp
Copyright 2019 KUMAMOTO University HRI All Rights Reserved.